Human mononuclear phagocytes comprise several subsets of dendritic cells (DCs), monocytes and macrophages. Distinguishing one population from another is challenging, especially in inflammed tissues, due to the promiscuous expression of phenotypic markers.
Introduction
Mononuclear phagocytes play a central role in the initiation and resolution of innate and adaptive immune responses. They comprise several populations of monocytes, macrophages and dendritic cells (DCs), which are classically defined by their phenotype and ontogeny (1) .
Monocytes are very plastic cells, and can differentiate into cells displaying typical features of macrophages or DCs, referred to as monocyte-derived macrophages (mo-Mac) and monocytederived DCs (mo-DC). This phenomenon has been described in vitro and in vivo, in both mouse and human (2) (3) (4) . Recently, high resolution single-cell technologies have revealed a new subset of blood DCs, termed DC3, displaying a mixed transcriptomic profile of classical DC (cDC) and monocyte genes (5) (6) (7) , reminiscent of that of mo-DC (8, 9) . Whether blood DC3 represent circulating mo-DC has been unclear.
Accumulating evidence suggests that monocyte-derived cells are involved in the pathogenesis of autoimmune and chronic inflammatory diseases (3) . However, their characterization in inflammed tissues is complicated by the promiscuous expression of numerous phenotypic markers, shared in particular with macrophages and cDCs. More specific markers are needed in order to advance our understanding of the respective properties of macrophages, cDCs and mo-DC, and ultimately to allow the manipulation of these cells for therapeutic strategies.
To identify novel markers for human mo-DC, we have used a synthetic library of humanized llama single domain antibodies. We identified one antibody, recognizing surface LSP-1, that stains specifically mo-DC, but not monocytes, macrophages, cDCs or DC3.
Results
In order to identify novel surface markers for human naturally-occuring mo-DC, we set up a phage display screen using a synthetic library of humanized llama single domain antibodies (termed VHH) (10) . We have previously shown that peritoneal ascites from cancer patients contain a population of mo-DC (8, 11) . Cells from tumor ascites were separated into DCs and all other cells (non-DCs), including tumor cells, macrophages, T cells and other immune cells.
The library was first depleted for phages binding to non-DCs, then phages binding to ascites DCs were screened ( fig 1A) . For subsequent studies, we produced the VHH of interest with a human Fc region containing a Streptavidin-binding peptide. Using this strategy, we identified a VHH antibody, termed "D4", that stains ascites DCs but not macrophages from the same samples ( fig 1B) . We have recently reported a culture model allowing the generation of in vitro counterparts of naturally-occuring mo-DC and mo-Mac, by culturing CD14 + monocytes with M-CSF, IL-4 and TNFα (9) . In this model, the VHH D4 stained mo-DC but not mo-Mac ( fig 1C) . We have also shown that the classical model of culturing monocytes with GM-CSF and IL-4 generates mo-DC that do not closely resemble the ones found in vivo in inflammatory fluids (9) . Consistent with this, the VHH D4 did not stain mo-DC generated with GM-CSF and IL-4 ( fig 1C) .
To determine the target of VHH D4 on the surface of mo-DC, we performed immunoprecipitation followed by proteomics mass spectrometry, using in vitro-generated mo-DC (cultured with M-CSF, IL-4 and TNFα) as a source of material. Mass spectrometry identified only one protein: Lymphocyte-Specific Protein 1 (LSP-1), a protein of predicted molecular weight of 60 kDa. To validate this result, we performed immunoprecipitation with VHH D4 on in vitro-generated mo-DC and mo-Mac, and revealed the immunoprecipitated proteins using Streptadivin (fig 2A) or a commercial anti-LSP-1 antibody ( fig 2B) . Both methods showed the same band around 55 kDa, only in immuno-precipitated material from mo-DC. This observation confirms that the VHH D4 binds LSP-1. LSP-1 is a F-actin binding protein reported to be expressed in all leukocytes (12) . Using our previously generated transcriptomic data (9), we confirmed that LSP1 was expressed at similar levels in ascites DC, ascites macrophages, in vitro mo-DC and mo-Mac generated with M-CSF, IL-4 and TNFα, in vitro mo-DC generated with GM-CSF and IL-4, and blood monocytes ( fig 2C) .
We then sought to address whether the VHH D4 could also stain other myeloid cells, in particular cDCs. We first used the VHH D4 on cells isolated from human tonsils. We have previously shown using single-cell RNA-seq analysis that tonsils contain cDC1 (CD141 high CD1c -DCs) and cDC2 (CD141 low CD1c + DCs), but no population of mo-DC (13) .
There was no significant staining of VHH D4 on cDC1, cDC2, nor tonsil macrophages ( fig   3A) . This result suggests that the VHH D4 is specific of mo-DC, and does not stain cDCs.
To extend these observations, we stained blood peripheral blood mononuclear cells. There was no significant staining on pDC, B cells nor CD16 + monocytes ( fig 3B) . It has recently been shown that blood CD1c + DCs are heterogenous and comprise CD1c + CD14 -CD163 -DCs (bona fide cDC2) and CD1c + CD14 + CD163 + DCs, termed DC3 (5) (6) (7) 14) . The VHH D4 did not show a significant staining on blood CD14 + monocytes, cDC2 nor DC3 ( fig 3C) , suggesting that DC3 are not blood-resident mo-DC.
Discussion
Using a synthetic library of humanized llama single domain antibodies, we have identified one antibody, recognizing LSP-1, that is specific for human mo-DC and distinguishes them from monocytes, macrophages, cDCs or DC3.
LSP-1 has been shown so far to reside on the cytoplasmic side of the plasma membrane (15) .
After membrane permeabilisation, LSP-1 can be detected by flow cytometry, in particular in B cells and macrophages (12) . Because our stainings with VHH D4 were performed without DC3 express a mixed transcriptional program with hallmark cDC2 genes (such as FCER1A, CD1C, CLEC10A) as well as typical monocyte genes (such as S100A8, S100A9, VCAN) (5-7), raising the question of their ontogeny, in particular whether DC3 correspond to circulating mo-DC. The VHH D4 did not show a significant staining on blood DC3, suggesting that they do not represent circulating blood mo-DC. This result is consistent with recent work showing the dependence of blood DC3 on Flt3-ligand (6), a characteristic feature of cDCs.
Together with our previous phenotypic characterization of mo-DC (9) and recent single-cell analysis of blood cDC2, DC3 and monocytes (5, 6) , our work enables a more precise phenotypic definition of human DC subsets. cDC2 can be defined as CD88 -CD14 -
DC3
as CD88 -CD14 + CD1c + FcεRI + CD226 -CD163 + sLSP1and mo-DC as CD88 low CD14 + CD1c + FcεRI + CD226 + CD163 -sLSP1 + .
Mo-DC have been identified in several inflammatory contexts in human tissues (3) . In cancer, the picture is less clear as DCs displaying a phenotype consistent with both mo-DC and DC3
have been reported in colorectal, breast and lung tumors (16) (17) (18) . DC3 are increased in the blood of patients with melanoma (7) and systemic lupus erythematosus (6), while blood DC3 infiltrate the lung alveolar space upon LPS-induced acute inflammation (19) . The respective role of these two DC subtypes in cancer or inflammation remains elusive. Our findings will pave the way for a better characterization of DC3 and mo-DC in pathological settings, ultimately allowing their manipulation for therapeutic strategies. Cell isolation. Tonsil samples were digested as described previously (20) . In brief, samples were cut into small fragments, digested with 0.1 mg mL -1 Liberase TL (Roche) in the presence of 0.1 mg mL -1 DNAse (Roche) for 40 minutes at room temperature before addition of 10 mM EDTA. Cells were filtered on a 40 µm cell strainer (BD Falcon) and washed. Light 
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